Log in to search using one of your social media accounts:

 

Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.

Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma. Dan Med J. 2015 Aug;62(8):B5144 Authors: Frøsig TM Abstract This review is focused on research within three different areas of tumor immunology: discovery of new T-cell epitopes and a new immunological antigen (reported in Paper I and II), elucidation of the immunological effects of treatment with a hypomethylating drug (reported in Paper III) and discovery of new conditional ligands (reported in Paper IV). Many melanoma-associated T-cell epitopes have been described, but 45% of these are restricted to human leukocyte antigen (HLA)-A2, leaving the remaining 36 different HLA molecules with only a few described T-cell epitopes each. Therefore we wanted to expand the number of T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7, all HLA molecules frequently expressed in Caucasians in Western Europe and Northern America. In Paper I we focused on the proteins gp100, Mart1, MAGE-A3, NY-ESO-1, tyrosinase and TRP-2, all melanoma-associated antigens frequently recognized by T cells from HLA-A2 patients. On contrary, in Paper II we wanted to investigate the protein Nodal as a novel immunological target. We took advantage of a T-cell epitope mapping platform in which HLA ligands are predicted by computer-based algorithms, further tested in the laboratory by an ELISA...
Source: Danish Medical Journal - Category: Journals (General) Tags: Dan Med J Source Type: research

Related Links:

CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States. PMID: 29469047 [PubMed - in process]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
The infection rate has begun to decline, but there are likely to be many deaths before the flu season finally ends.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Influenza Epidemics Vaccination and Immunization Centers for Disease Control and Prevention United States Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Urology Commentary Source Type: news
February 23, 2018—(BRONX, NY)—Earlier this week, in a crowded conference room in the Price Center/Block Pavilion, members of the Einstein-Montefiore community hosted a special visit from U.S. Congressman Joseph Crowley (D-NY, 14th District). At his office’s request, Rep. Crowley met with more than a dozen BOLD Buddies, volunteer peer mentors who provide support for cancer patients and survivors in the Bronx. Members of the group shared their personal stories and explained commitment to offer their support, hope and encouragement to others facing cancer and treatment at all stages of disease.
Source: Einstein News - Category: Universities & Medical Training Source Type: news
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a doctor.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Norton Healthcare is customizing treatment rooms for the best patient and provider experience.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Cancer and Genetics Immuno Oncology Source Type: news
Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Melanoma News Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Computers | Databases & Libraries | General Medicine | Genetics | Laboratory Medicine | Melanoma | Men | Myelodysplastic Syndrome | Myeloproliferative Disorders | Skin Cancer | Vaccines